BME:ABB

Stock Analysis Report

Executive Summary

AB-Biotics, S.A. operates as a biotechnology company in Spain.

Rewards

PE ratio (26.4x) is below the Biotechs industry average (29.2x)

Became profitable this year

Risk Analysis

High level of non-cash earnings

Does not have a meaningful market cap (€63M)



Snowflake Analysis

Flawless balance sheet with acceptable track record.

Share Price & News

How has AB-Biotics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ABB has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

ABB

-1.2%

ES Biotechs

0.2%

ES Market


1 Year Return

59.2%

ABB

25.3%

ES Biotechs

6.5%

ES Market

Return vs Industry: ABB exceeded the Spanish Biotechs industry which returned 25.3% over the past year.

Return vs Market: ABB exceeded the Spanish Market which returned 6.5% over the past year.


Shareholder returns

ABBIndustryMarket
7 Day0%-1.2%0.2%
30 Day0.8%5.2%0.2%
90 Day0%9.2%3.4%
1 Year59.2%59.2%26.5%25.3%10.4%6.5%
3 Year208.6%208.6%42.7%39.9%14.5%3.7%
5 Year157.7%157.7%89.5%85.2%12.7%-6.4%

Price Volatility Vs. Market

How volatile is AB-Biotics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is AB-Biotics undervalued compared to its fair value and its price relative to the market?

26.42x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ABB's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ABB's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ABB is good value based on its PE Ratio (26.4x) compared to the Biotechs industry average (29.2x).

PE vs Market: ABB is poor value based on its PE Ratio (26.4x) compared to the Spanish market (17.2x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ABB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ABB is overvalued based on its PB Ratio (7.9x) compared to the ES Biotechs industry average (4.4x).


Next Steps

Future Growth

How is AB-Biotics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

15.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as AB-Biotics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has AB-Biotics performed over the past 5 years?

29.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ABB has a high level of non-cash earnings.

Growing Profit Margin: ABB became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: ABB has become profitable over the past 5 years, growing earnings by 29% per year.

Accelerating Growth: ABB has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: ABB has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: ABB's Return on Equity (30.1%) is considered high.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is AB-Biotics's financial position?


Financial Position Analysis

Short Term Liabilities: ABB's short term assets (€7.2M) exceed its short term liabilities (€3.5M).

Long Term Liabilities: ABB's short term assets (€7.2M) exceed its long term liabilities (€4.1M).


Debt to Equity History and Analysis

Debt Level: ABB's debt to equity ratio (2.3%) is considered satisfactory.

Reducing Debt: ABB had negative shareholder equity 5 years ago, but is now positive and has therefore improved.

Debt Coverage: ABB's debt is well covered by operating cash flow (223.4%).

Interest Coverage: ABB's interest payments on its debt are well covered by EBIT (6.6x coverage).


Balance Sheet

Inventory Level: ABB has a low level of unsold assets or inventory.

Debt Coverage by Assets: ABB's debt is covered by short term assets (assets are 39.3x debt).


Next Steps

Dividend

What is AB-Biotics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.3%markettop25%5.5%industryaverage1.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate ABB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ABB's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ABB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ABB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ABB's dividend in 3 years as they are not forecast to pay a notable one for the Spanish market.


Next Steps

Management

What is the CEO of AB-Biotics's salary, the management and board of directors tenure and is there insider trading?


CEO

Sergi Audivert Brugué 0

0yrs

Tenure

0

Mr. Sergi Audivert Brugué serves as a Co-Founder, Co-Chief Executive Officer and Director at AB-Biotics SA and served as its Chief Operating Officer. Mr. Audivert serves as Chairman of AB-Biotics S.A. Mr.  ...


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Management Team

  • Miquel Àngel Bonachera Sierra

    Co-Founder

    • Tenure: 0yrs
  • Sergi Audivert Brugué

    Co-Founder

    • Tenure: 0yrs
  • Carlos de Lecea

    Managing Director

    • Tenure: 0yrs
  • José María de Paz

    Non-Board Secretary

    • Tenure: 0yrs
  • Mercè Mengual

    Marketing Director

    • Tenure: 0yrs
  • Jordi Riera

    Chief Business Development Officer

    • Tenure: 0yrs
  • Mario Saldanha

    Chief Financial Officer

    • Tenure: 0.9yrs

Board Members

  • Shinji Mizusawa

    Director

    • Tenure: 0yrs
  • Miquel Àngel Bonachera Sierra

    Co-Founder

    • Tenure: 0yrs
  • Sergi Audivert Brugué

    Co-Founder

    • Tenure: 0yrs
  • Kazuhiko Fujii

    Director

    • Tenure: 0yrs
  • Hitoshi Yahara

    Director

    • Tenure: 0yrs
  • Juan Ramón Ramos Raich

    Independent Director

    • Tenure: 0yrs
  • José María Echarri Torres

    Independent Director

    • Tenure: 0yrs
  • Philip Claes

    Director

    • Tenure: 0yrs
  • Agustí Vilajoana Mas

    Independent Director

    • Tenure: 0yrs

Company Information

AB-Biotics, S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: AB-Biotics, S.A.
  • Ticker: ABB
  • Exchange: BME
  • Founded: 2004
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €62.545m
  • Shares outstanding: 12.51m
  • Website: https://www.ab-biotics.com

Number of Employees


Location

  • AB-Biotics, S.A.
  • ESADE CREAPOLIS BUSINESS PARK
  • Avinguda de la Torre Blanca, 57, OFFICE 3B11
  • Barcelona
  • Catalonia
  • 8172
  • Spain

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ABBBME (Bolsas y Mercados Espanoles)YesSeries A sharesESEURJul 2010

Biography

AB-Biotics, S.A. operates as a biotechnology company in Spain. The company offers probiotic products, including cardiometabolic products comprising AB-LIFE; oral care products that include AB-Dentalac and  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/12/06 21:50
End of Day Share Price2019/11/22 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.